Trial Profile
Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2023
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Cabozantinib (Primary) ; Regorafenib (Primary)
- Indications Gastrointestinal cancer; Head and neck cancer; Non-small cell lung cancer; Tumours; Urogenital cancer
- Focus Therapeutic Use
- 17 Aug 2022 Status changed from active, no longer recruiting to completed.
- 17 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 17 Aug 2021 Planned End Date changed from 30 Dec 2021 to 30 Dec 2023.